Clinical Trial Update: A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase I single ascending dose study of intravitreal KVD001 in subjects with diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• KVD001

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Diabetic Macular Edema | Phase 1 | Status: COMPLETED